National Hemophilia Foundation

Website provided by National Hemophilia Foundation and its education partners

CCSC Presents: Copay Accumulators and the Impact on High-Cost, Rare Diseases

View the webcast now:



Download the slides here:


***Sign up to become a member and receive updates, access to useful resources, and practice tools.*** 

Previously Held Live Webcast
Thursday, June 20, 2019
12:00 pm-1:00 pm ET

Program Overview

Accumulator adjustment programs target manufacturer copay assistance programs available for specialty drugs by no longer allowing them to count towards a member’s deductible or out-of-pocket responsibilities. For patients who depend on life saving medications that are high cost/high value (life and death), such as hemophilia, these programs absolutely threaten adherence, posing significant unintended consequences to patients and run the real risk of actually increasing the total cost of care for the purchasers of health care.

As a result, some states have implemented copay accumulator adjustment bans, with others expected to follow; and CMS has issued the NPBB final rule, beginning January 1, 2020, stating insurers may not implement these programs for specialty drugs which have no generics; and while they may implement the programs if there are generics, they can’t penalize patients if the generic is ineffective. 

This webcast will outline the current landscape of copay accumulator programs with unique perspectives from our expert faculty presenters. The webcast is provided by the Comprehensive Care Sustainability Collaborative (CCSC). The aim of CCSC is to provide payers, purchasers, and other key stakeholders with knowledge and skills crucial for managing the high costs associated with hemophilia and other bleeding disorders.

Who Should Attend

  • Employer groups
  • Benefit managers
  • Other Key Stakeholders Involved in the Management of Hemophilia

Learning Objectives

  • Describe the current environment of copay accumulator programs
  • Explain how pharmacy benefit designs contribute value to overall population health outcomes
  • Cite examples of the unintended consequences of accumulator adjustment programs


  • Opening Comments
    Kollet Koulianos, MBA

  • Copay Accumulator Program Overview
    James Kenney, Jr., RPh, MBA

  • The Population Health and Well Being Impact of Pharmacy Benefit Designs
    Tom Sondergeld, MHA

  • A Patient Advocacy Viewpoint of Accumulator Adjustment Programs
    Kollet Koulianos, MBA

  • Audience Q&A
    Faculty Panel

Expert Panel

James Kenney, Jr., RPh, MBA
JTKenney, LLC

Kollet Koulianos, MBA
Senior Director Payer Relations
National Hemophilia Foundation

Tom Sondergeld
Vice President HRIS
Global Benefits & Mobility
Walgreens Boots Alliance, Inc